Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Pure Bioscience's operating income for the twelve months ending Jul 31, 2026 was -$2.08M. For fiscal 2026 it was -$2.08M. The highest annual figure on record is $4.00K in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -$2.08M | – |
| FY2025 | Jul 31, 2025 | -$2.27M | – |
| FY2024 | Jul 31, 2024 | -$3.19M | – |
| FY2023 | Jul 31, 2023 | -$3.94M | – |
| FY2022 | Jul 31, 2022 | -$3.72M | – |
| FY2021 | Jul 31, 2021 | -$2.31M | -57875.0% |
| FY2020 | Jul 31, 2020 | $4.00K | – |
| FY2019 | Jul 31, 2019 | -$5.59M | – |
| FY2018 | Jul 31, 2018 | -$7.04M | – |
| FY2017 | Jul 31, 2017 | -$6.01M | – |
| FY2016 | Jul 31, 2016 | -$7.06M | – |
| FY2015 | Jul 31, 2015 | -$7.64M | – |
| FY2014 | Jul 31, 2014 | -$11.90M | – |
| FY2013 | Jul 31, 2013 | -$7.34M | – |
| FY2012 | Jul 31, 2012 | -$8.75M | – |
| FY2011 | Jul 31, 2011 | -$8.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -$503.00K | – |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -$518.00K | – |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -$683.00K | – |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -$379.00K | – |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -$336.00K | – |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$584.00K | – |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -$725.00K | – |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -$627.00K | – |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -$699.00K | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$817.00K | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$964.00K | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$711.00K | – |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -$1.02M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$875.00K | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$1.06M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$986.00K | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$1.23M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$759.00K | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$940.00K | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$795.00K | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$728.00K | -155.0% |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$810.00K | -270.9% |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -$594.00K | – |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -$179.00K | – |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | $1.32M | – |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | $474.00K | – |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -$663.00K | – |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -$1.13M | – |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -$822.00K | – |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -$912.00K | – |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -$1.29M | – |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -$2.56M | – |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -$1.38M | – |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -$1.71M | – |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -$2.03M | – |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -$1.93M | – |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -$1.41M | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -$1.59M | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | -$1.40M | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | -$1.60M | – |
See a number that looks wrong?